02 January 2016
Thanks to the contribution of the Quebec City authorities, the CHU de Québec-Université Laval and the biopharmaceutical company Medicago, the Infectious Disease Research Centre will soon be equipped with a level 3 biological containment laboratory that will allow the safe study of aerosol-transmissible pathogens such as SARS, West Nile virus, typhus, tuberculosis, anthrax or yellow fever.
The investment will allow the acquisition of adequate decontamination equipment necessary to make existing facilities operational. These facilities will also allow IDRC researchers and the Quebec City scientific community to conduct cutting-edge research on emerging pathogens such as MERS-CoV and new strains of influenza. This research will facilitate the creation of new effective vaccines, the identification of mechanisms for the development of antimicrobial resistance and a better understanding of the pathologies associated with these new diseases.